Receive The Newest Study Notifications

First-Ever Double-Blind, Randomized Study Titled, “Effects of a CBD-containing Supercritical Fluid Extract of Hemp on Markers of Optimal Wellness, Stress Resilience, and Recovery in Healthy Subjects,” Validates Benefits of Daily Supplementation with CV Sciences’...

- Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrolment of 104 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic SteatoHepatitis (NASH) across 20 clinical sites in the United States...

- Detailed data from this trial will be presented at a medical meeting later this year - RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall...

Earlier today, CyTuVax B.V. (Maastricht, The Netherlands) released the results of the HBAI20 Phase 2 “BE-Responder” trial. This trial focused on so-called non-responders to hepatitis B vaccination, persons who have been vaccinated with at least one complete...

- Significant unmet need for new effective therapies exists in ulcerative colitis - ELEVATE UC clinical trial sites continue to initiate  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of...

A decade ago, the United Nations declared June 19 to be World Sickle Cell Awareness Day—and for good reason. This genetic condition warps round red blood cells into crescent-shaped ones that disrupt blood flow, damage organs, and cause frequent bouts of pain. Millions...

Study sponsored by Myotonic Dystrophy Clinical Research Network will advance understanding of disease progression and enable development of clinical outcome assessments Patients with DM1 aged 18-70 encouraged to enroll at study sites in U.S. and Europe Dyne...

The Standard vs ultrasound-assisted catheter thrombolysis for submassive pulmonary embolism(SUNSET sPE) trial, is an ongoing randomised, head-to-head, single-blinded clinical trial comparing ultrasound-assisted thrombolysis to standard catheter-directed thrombolysis....

– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75%...

BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated....

 Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase...

-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host webcast and conference call today at 8:30 a.m. ET /...

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included in the "Novel strategies in multiple myeloma" session and was led by Professor Paul G....

RBM-007 was well-tolerated with no dose-limiting toxicities, no systemic or ocular serious adverse events. Seven out of nine subjects showed evidence of RBM-007 bioactivity, in terms of any vision gain or ≥50 µm improvement in central retinal thickness after a single...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical...

-- Confirmed 77% ORR per central review in advanced SM -- -- Consistent and profound improvements on measures of mast cell burden across all disease subtypes, including in 15 indolent and smoldering SM patients -- -- Median overall survival not reached with ongoing...

- Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL) - STRO-001 is the first antibody-drug conjugate generated with Sutro's novel cell-free protein...

 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell...

 -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapies, such as...

Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it has initiated its Phase I Clinical Trial...